Back to search
FDAFDA · Food and drugs·Recall number D-0235-2022

Clonidine Transdermal System, USP 0.1 mg/day, 4 patches per carton, Rx only, Manufactured by: Actavis Laboratories, UT Inc., Salt Lake City, UT, Distributed by: Actavis Pharma, Inc., Parsippany, NJ NDC 0591-3508-04

Published November 24, 2021 · Recall initiated: October 28, 2021

Summary

FDA records drug Class III recall D-0235-2022, published November 24, 2021 and initiated October 28, 2021. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 64,978 patches; Lot: Lot# 1369117B, exp. date 11/2021. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email if CLONIDINE TRANSDERMAL SYSTEM has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
CLONIDINE TRANSDERMAL SYSTEM
Manufacturer
Teva Pharmaceuticals USA
Distributor
Nationwide and Puerto Rico
Lot
Lot# 1369117B, exp. date 11/2021
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Clonidine Transdermal System, USP 0.1 mg/day, 4 patches per carton, Rx only, Manufactured by: Actavis Laboratories, UT Inc., Salt Lake City, UT, Distributed by: Actavis Pharma, Inc., Parsippany, NJ NDC 0591-3508-04 recalled?

Yes. FDA published recall D-0235-2022 on November 24, 2021. Reported hazard: Failed Impurities/Degradation Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: CLONIDINE TRANSDERMAL SYSTEM.